Bank Julius Baer & Co. Ltd Zurich Sells 5,664 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bank Julius Baer & Co. Ltd Zurich reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 8.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,406 shares of the medical equipment provider's stock after selling 5,664 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned 0.09% of Lantheus worth $6,068,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Summit Securities Group LLC purchased a new stake in Lantheus in the fourth quarter worth about $37,000. Signaturefd LLC grew its holdings in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares during the period. Hughes Financial Services LLC purchased a new stake in Lantheus in the first quarter worth about $81,000. UMB Bank n.a. grew its holdings in Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after purchasing an additional 381 shares during the period. Finally, Blue Trust Inc. grew its holdings in Lantheus by 117.7% in the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after purchasing an additional 633 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

Lantheus stock traded up $2.00 during midday trading on Friday, reaching $72.93. 615,452 shares of the company traded hands, compared to its average volume of 1,083,256. The firm has a market capitalization of $5.05 billion, a price-to-earnings ratio of 20.72 and a beta of 0.12. The business has a 50 day moving average of $78.06 and a two-hundred day moving average of $88.72. Lantheus Holdings, Inc. has a 12 month low of $69.12 and a 12 month high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company earned $1.69 EPS. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LNTH. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Truist Financial cut their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a report on Monday, June 23rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.